BioCryst Pharmaceuticals Inc.

5.51-0.6200-10.11%Vol 16.19M1Y Perf -43.71%
Dec 6th, 2023 16:00 DELAYED
BID5.36 ASK5.82
Open5.50 Previous Close6.13
Pre-Market- After-Market5.46
 - -  -0.05 -0.91%
Target Price
16.89 
Analyst Rating
Strong Buy 1.50
Potential %
206.53 
Finscreener Ranking
★★★★+     56.33
Insiders Trans % 3/6/12 mo.
-/-100/-75 
Value Ranking
★★+     47.83
Insiders Value % 3/6/12 mo.
-/-100/-89 
Growth Ranking
★★★★     59.52
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-87 
Income Ranking
 —    -
Price Range Ratio 52W %
8.65 
Earnings Rating
Sell
Market Cap1.13B 
Earnings Date
2nd Nov 2023
Alpha-0.00 Standard Deviation0.22
Beta1.87 

Today's Price Range

4.985.71

52W Range

4.8312.75

5 Year PE Ratio Range

-6.70-9.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
12.89%
1 Month
3.37%
3 Months
-12.43%
6 Months
-28.14%
1 Year
-43.71%
3 Years
0.49%
5 Years
-31.51%
10 Years
3.37%

TickerPriceChg.Chg.%
BCRX5.51-0.6200-10.11
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
Financial StrengthValueIndustryS&P 500US Markets
5.80
6.20
0.48
2.40
-1.10
Leverage Ratio -2.60
ProfitabilityValueIndustryS&P 500US Markets
98.10
-40.70
-40.20
-406.70
-91.79
RevenueValueIndustryS&P 500US Markets
191.28M
1.03
67.93
32.26
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.25-0.1924.00
Q02 2023-0.25-0.244.00
Q01 2023-0.30-0.286.67
Q04 2022-0.19-0.38-100.00
Q03 2022-0.32-0.2328.12
Q02 2022-0.36-0.3211.11
Q01 2022-0.39-0.40-2.56
Q04 2021-0.31-0.40-29.03
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.24-4.35Negative
12/2023 FY-0.942.08Positive
3/2024 QR-0.28-27.27Negative
12/2024 FY-0.67-39.58Negative
Next Report Date-
Estimated EPS Next Report-0.25
Estimates Count5
EPS Growth Next 5 Years %30.00
Volume Overview
Volume16.19M
Shares Outstanding204.81K
Shares Float195.80M
Trades Count82.42K
Dollar Volume88.48M
Avg. Volume2.83M
Avg. Weekly Volume3.17M
Avg. Monthly Volume2.74M
Avg. Quarterly Volume2.57M

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) stock closed at 6.13 per share at the end of the most recent trading day (a -0.97% change compared to the prior day closing price) with a volume of 3.22M shares and market capitalization of 1.13B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 140 people. BioCryst Pharmaceuticals Inc. CEO is Jon P. Stonehouse.

The one-year performance of BioCryst Pharmaceuticals Inc. stock is -43.71%, while year-to-date (YTD) performance is -46.6%. BCRX stock has a five-year performance of -31.51%. Its 52-week range is between 4.825 and 12.745, which gives BCRX stock a 52-week price range ratio of 8.65%

BioCryst Pharmaceuticals Inc. currently has a PE ratio of -11.30, a price-to-book (PB) ratio of 56.59, a price-to-sale (PS) ratio of 10.36, a price to cashflow ratio of -, a PEG ratio of -0.38, a ROA of -49.34%, a ROC of -96.99% and a ROE of 105.31%. The company’s profit margin is -91.79%, its EBITDA margin is -40.20%, and its revenue ttm is $191.28 Million , which makes it $1.03 revenue per share.

Of the last four earnings reports from BioCryst Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. BioCryst Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BioCryst Pharmaceuticals Inc. is Strong Buy (1.5), with a target price of $16.89, which is +206.53% compared to the current price. The earnings rating for BioCryst Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioCryst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioCryst Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.81, ATR14 : 0.35, CCI20 : 135.56, Chaikin Money Flow : 0.03, MACD : 0.04, Money Flow Index : 64.34, ROC : 19.26, RSI : 59.73, STOCH (14,3) : 83.22, STOCH RSI : 0.91, UO : 60.15, Williams %R : -16.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioCryst Pharmaceuticals Inc. in the last 12-months were: Alane Barnes (Sold 4 175 shares of value $45 424 ), Anthony Doyle (Sold 5 700 shares of value $62 130 ), Charles K. Gayer (Sold 6 100 shares of value $66 490 ), Helen M. Thackray (Sold 17 125 shares of value $150 091 ), Jon P. Stonehouse (Option Excercise at a value of $644 997), Jon P. Stonehouse (Sold 114 100 shares of value $1 191 690 ), Kenneth B. Lee (Option Excercise at a value of $25 650), Michael L. Jones (Sold 445 shares of value $4 851 ), Nancy J. Hutson (Sold 12 866 shares of value $103 443 ), Stonehouse Jon (Option Excercise at a value of $644 997), Stonehouse Jon (Sold 100 000 shares of value $1 038 000 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (66.67 %)
7 (70.00 %)
7 (70.00 %)
Moderate Buy
2 (16.67 %)
2 (20.00 %)
1 (10.00 %)
Hold
2 (16.67 %)
1 (10.00 %)
2 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.40
Strong Buy
1.50

BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

CEO: Jon P. Stonehouse

Telephone: +1 919 859-1302

Address: 4505 Emperor Boulevard, Durham 27703, NC, US

Number of employees: 140

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

53%47%

Bearish Bullish

61%39%

 

TipRanks News for BCRX

Mon, 18 Sep 2023 10:45 GMT BioCryst (BCRX) was upgraded to a Buy Rating at RBC Capital

- TipRanks. All rights reserved.

News

Stocktwits